121 related articles for article (PubMed ID: 21173602)
1. Renal cell cancer: the unmet needs.
Durán I
Anticancer Drugs; 2011 Jan; 22 Suppl 1():S1-3. PubMed ID: 21173602
[No Abstract] [Full Text] [Related]
2. ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.
Roulin D; Demartines N; Dormond O
Biochem Soc Trans; 2011 Apr; 39(2):492-4. PubMed ID: 21428926
[TBL] [Abstract][Full Text] [Related]
3. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
Bukowski RM
Clin Genitourin Cancer; 2007 Sep; 5(6):359-61. PubMed ID: 17956708
[No Abstract] [Full Text] [Related]
4. mTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome?
Eimer C; Gerullis H; Heuck C; Otto T
Anticancer Drugs; 2011 Jan; 22(1):18-23. PubMed ID: 21037468
[TBL] [Abstract][Full Text] [Related]
5. Sequencing therapy in metastatic renal cell cancer.
Escudier B; Gore M
Semin Oncol; 2013 Aug; 40(4):465-71. PubMed ID: 23972710
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy for renal cell cancer: current perspectives.
van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
[TBL] [Abstract][Full Text] [Related]
7. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
Grgic T; Mis L; Hammond JM
Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
[TBL] [Abstract][Full Text] [Related]
8. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
9. [Role of mTOR inhibition in the treatment of metastatic renal cell carcinoma].
Mizuno R; Miyajima A; Oya M
Nihon Jinzo Gakkai Shi; 2012; 54(5):581-5. PubMed ID: 22991836
[No Abstract] [Full Text] [Related]
10. Update on the use of mTOR inhibitors in renal cell carcinoma.
Rini BI
Clin Adv Hematol Oncol; 2008 Oct; 6(10):722-4. PubMed ID: 18997660
[No Abstract] [Full Text] [Related]
11. Future directions in renal cell carcinoma: 2011 and beyond.
Cho DC; Atkins MB
Hematol Oncol Clin North Am; 2011 Aug; 25(4):917-35. PubMed ID: 21763974
[TBL] [Abstract][Full Text] [Related]
12. Everolimus- and temsirolimus-associated enteritis: report of three cases.
Parithivel K; Ramaiya N; Jagannathan JP; O'Regan K; Krajewski K; Fisher D; Choueiri TK; Jacobsen E
J Clin Oncol; 2011 May; 29(14):e404-6. PubMed ID: 21357780
[No Abstract] [Full Text] [Related]
13. Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices.
Appleby L; Morrissey S; Bellmunt J; Rosenberg J
Hematol Oncol Clin North Am; 2011 Aug; 25(4):893-915. PubMed ID: 21763973
[TBL] [Abstract][Full Text] [Related]
14. Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012;61:826-33.
Procopio G; Verzoni E; De Braud F
Eur Urol; 2012 Jul; 62(1):e5-6; author reply e7-8. PubMed ID: 22487015
[No Abstract] [Full Text] [Related]
15. Temsirolimus for advanced renal cell carcinoma.
Figlin RA
Clin Adv Hematol Oncol; 2007 Nov; 5(11):893. PubMed ID: 18185488
[No Abstract] [Full Text] [Related]
16. Selected toxicities of targeted therapies: presentation and management.
Kollmannsberger C; Mitchell T
Semin Oncol; 2013 Aug; 40(4):499-510. PubMed ID: 23972714
[TBL] [Abstract][Full Text] [Related]
17. Molecularly targeted agents for renal cell carcinoma: the next generation.
Cowey CL; Hutson TE
Clin Adv Hematol Oncol; 2010 May; 8(5):357-60, 361-4. PubMed ID: 20551895
[TBL] [Abstract][Full Text] [Related]
18. Against: The case for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma.
Carver BS
J Urol; 2009 Sep; 182(3):833-4. PubMed ID: 19616224
[No Abstract] [Full Text] [Related]
19. Temsirolimus (Torisel) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
[No Abstract] [Full Text] [Related]
20. Kinase inhibitors in the treatment of renal cell carcinoma.
Larkin JM; Eisen T
Crit Rev Oncol Hematol; 2006 Dec; 60(3):216-26. PubMed ID: 16860997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
